Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey

• Published in: Blood cell therapy Vol. 6; no. 4; pp. 114 - 123
• Main Authors: Iida, Minako, Liu, Kaiyan, Huang, Xiao Jun, Huang, He, Kuwatsuka, Yachiyo, Moon, Joon Ho, Lee, Jong Wook, Lakshmi, Kavitha M, Dodds, Anthony, Wilcox, Leonie, Ko, Bor-Sheng, Hamidieh, Amir Ali, Behfar, Maryam, Ho, Kim Wah, Bunworasate, Udomsak, Ho, Aloysius, Farzana, Tasneem, Sim, Joycelyn, Dung, Phu Chi, Akter, Mafruha, Ratnayake, Wasantha, Bravo, Marjorie Rose, Gyi, Aye Aye, Santosa, Damai, Poudyal, Bishesh Sharma, Batshkh, Khishigjargal, Srivastava, Alok, Okamoto, Shinichiro, Atsuta, Yoshiko
• Format: Journal Article
• Language: English
• Published: Japan Asia-Pacific Blood and Marrow Transplantation Group 25-11-2023
• Subjects: Original; Asia-Pacific region; stem cell sources; hematopoietic stem cell transplant
• ISSN: 2432-7026; 2432-7026
• DOI: 10.31547/bct-2023-015

The number of hematopoietic stem cell transplantations (HCTs) is increasing annually worldwide, and the Asia-Pacific (AP) region is no exception. We report on the absolute number of HCTs in 2018 and 2019 and the trends in graft selection and disease indication in the past few decades. In 2018, 24,292 HCTs were performed in the AP region, of which 8,754 (36.0%) were autologous and 15,538 (64.0%) were allogeneic. Among the allogeneic HCTs, 10,552 (67.9%) of the recipients were related to their donors, whereas 4,986 (32.1%) were unrelated. In 2019, 27,583 HCTs were reported, of which 17,613 (63.9%) were allogeneic and 9,970 (36.1%) were autologous. Although, in 2010, there was a nearly equal number of related and unrelated HCTs, the difference has shown an annual increase, with more than double (2.05) the number of related than unrelated HCTs in 2019. Recent trends in the AP region show that peripheral blood has overwhelmingly surpassed the bone marrow as a graft source for both related and unrelated HCTs, with the haploidentical donor type being preferred; however, their trends in each country/region were quite different among countries/regions. In 2019, the main conditions requiring HCT were acute myelogenous leukemia (n=6,629 [24.0%]), plasma cell disorders (PCD) (n=4,935 [17.9%]), malignant lymphoma (ML) (n=4,106 [14.9%]), acute lymphoblastic leukemia (AML) (n=3,777 [13.7%]), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm (n=1,913 [6.9%]), severe aplastic anemia (n=1,671 [6.1%]), and hemoglobinopathy (n=910 [3.3%]). PCD and ML were the main indications for autologous HCT, and the number of PCD cases has grown more prominent than the corresponding of ML. The increased number of allogeneic transplants for hemoglobinopathy remains prominent, as well as that of AML and acute lymphocytic leukemia for the past 5 years. There was a significant regional variation in the number of facilities performing HCTs, ranging from one in Mongolia and Nepal to 313 in Japan, and differing regional densities varying from 0.1 in Indonesia and Pakistan to 24.7 in Japan. The total transplant density per 10 million population in each country/region also differed (0.2 in Indonesia and 627 in New Zealand). This annual Activity Survey aims to help all participating countries/regions understand the changes in HCT, serve as an asset in promoting HCT activities in the AP region, and be used as a reference for comparison with other registries from Europe and the United States.